Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
16.57
+0.01 (0.06%)
May 5, 2026, 1:56 PM EDT - Market open
Takeda Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 4,464,580 | 4,581,550 | 4,263,760 | 4,027,480 | 3,569,010 | 3,197,810 | |
Revenue Growth (YoY) | -1.13% | 7.45% | 5.87% | 12.85% | 11.61% | -2.84% |
Cost of Revenue | 1,547,940 | 1,580,220 | 1,426,680 | 1,244,070 | 1,106,850 | 994,308 |
Gross Profit | 2,916,650 | 3,001,330 | 2,837,080 | 2,783,410 | 2,462,160 | 2,203,500 |
Selling, General & Admin | 1,088,140 | 1,104,770 | 1,053,820 | 997,309 | 886,361 | 875,663 |
Depreciation & Amortization Expenses | 609,493 | 643,233 | 652,117 | 542,443 | 472,915 | 421,864 |
Research & Development | 696,573 | 730,227 | 729,924 | 633,325 | 526,087 | 455,833 |
Other Operating Expenses | 175,082 | 180,521 | 187,148 | 119,823 | 115,952 | -59,125 |
Total Operating Expenses | 2,569,288 | 2,658,751 | 2,623,009 | 2,292,900 | 2,001,315 | 1,694,235 |
Operating Income | 347,461 | 342,586 | 214,075 | 490,505 | 460,844 | 509,269 |
Interest Income | 222,539 | 42,563 | 58,566 | 54,283 | 8,333 | 105,597 |
Interest Expense | -364,696 | -210,065 | -219,850 | -169,698 | -166,607 | -248,631 |
Total Non-Operating Income (Expense) | -142,157 | -167,502 | -161,284 | -115,415 | -158,274 | -143,034 |
Pretax Income | 205,404 | 175,084 | 52,791 | 375,090 | 302,571 | 366,235 |
Provision for Income Taxes | 92,154 | 66,941 | -91,406 | 58,052 | 72,405 | -9,936 |
Net Income | 112,841 | 107,928 | 144,067 | 317,017 | 230,059 | 376,005 |
Minority Interest in Earnings | -92 | 215 | 130 | 21 | 107 | 166 |
Net Income to Common | 112,841 | 107,928 | 144,067 | 317,017 | 230,059 | 376,005 |
Net Income Growth | 8.24% | -25.09% | -54.55% | 37.80% | -38.81% | 749.90% |
Shares Outstanding (Basic) | 3,152 | 3,158 | 3,129 | 3,104 | 3,127 | 3,124 |
Shares Outstanding (Diluted) | 3,176 | 3,211 | 3,161 | 3,140 | 3,154 | 3,147 |
Shares Change (YoY) | 0.78% | 1.58% | 0.67% | -0.46% | 0.23% | 0.47% |
EPS (Basic) | 35.97 | 34.18 | 46.05 | 102.14 | 73.57 | 120.36 |
EPS (Diluted) | 35.41 | 33.62 | 45.58 | 100.97 | 72.94 | 119.48 |
EPS Growth | -46.05% | -26.25% | -54.86% | 38.44% | -38.96% | 745.88% |
Shares Outstanding | 3,159 | 3,147 | 3,138 | 3,109 | 3,165 | 3,127 |
Free Cash Flow | 1,010,630 | 856,387 | 540,924 | 836,499 | 999,853 | 899,725 |
Free Cash Flow Growth | 18.01% | 58.32% | -35.34% | -16.34% | 11.13% | 65.80% |
Free Cash Flow Per Share | 318.17 | 266.73 | 171.14 | 266.42 | 316.98 | 285.89 |
Dividends Per Share | 198.000 | 196.000 | 188.000 | 180.000 | 180.000 | 180.000 |
Dividend Growth | 1.02% | 4.25% | 4.44% | - | - | - |
Gross Margin | 65.33% | 65.51% | 66.54% | 69.11% | 68.99% | 68.91% |
Operating Margin | 7.78% | 7.48% | 5.02% | 12.18% | 12.91% | 15.93% |
Profit Margin | 2.53% | 2.36% | 3.38% | 7.87% | 6.45% | 11.76% |
FCF Margin | 22.64% | 18.69% | 12.69% | 20.77% | 28.01% | 28.14% |
EBITDA | 1,094,490 | 1,103,980 | 942,077 | 1,154,910 | 1,044,000 | 1,068,940 |
EBITDA Margin | 24.51% | 24.10% | 22.10% | 28.68% | 29.25% | 33.43% |
EBIT | 347,461 | 342,586 | 214,075 | 490,505 | 460,844 | 509,269 |
EBIT Margin | 7.78% | 7.48% | 5.02% | 12.18% | 12.91% | 15.93% |
Effective Tax Rate | 44.86% | 38.23% | -173.15% | 15.48% | 23.93% | -2.71% |
Updated Jan 30, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.